Abstract
Background & Aims : To clarify whether aspirin-dialminate administration suppresses the serum phosphorus (P) level in hemodialysis patients. Methods : The subjects were 13 hemodialysis patients who required antiplatelet therapy with aspirin-dialminate. Serum P and calcium (Ca) levels and the Ca-P product were measured after aspirin-dialminate administration, and they were compared with the levels before treatment. Results : Serum P level decreased from 5.66±1.45 to 4.72 ± 0.92 mg/dL, and the Ca-P product decreased from 53.4± 16.0 to 44.3 ± 10.3 after one month of aspirin-dialminate intake (p < 0.05), however, these effects were not maintained after 2 and 3 months. Serum Ca levels showed no change through the period of the present study. Conclusions : Aspirin-dialminate has an intermittent and limited effect on suppressing the serum P level and the Ca-P product in hemodialysis patients.
